Concentrations of amoxycillin in serum and dialysate of uraemic patients undergoing peritoneal dialysis

Jones, Roy; Cundy, Tim; Bullock, R. E.; Brown, Christopher; Dufton, J; Majer, R.V.; Parsons, V.; Bridgman, K M

doi:10.1016/s0163-4453(79)91241-6

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results have been found with amoxycillin administered to pa tients with peritonitis undergoing intermittent peritoneal dialysis [Jones et al, 1979].…”

Section: Discussionsupporting

confidence: 82%

Pharmacokinetics of Intraperitoneal Cefotaxime Treatment of Peritonitis in Patients on Continous Ambulatory Peritoneal Dialysis

Petersen¹,

Stewart

Catto

et al. 1985

Nephron

View full text Add to dashboard Cite

The pharmacokinetics of intraperitoneal cefotaxime as the sole therapy in patients on continous ambulatory peritoneal dialysis with peritonitis have been examined. The mean plasma concentrations achieved following 1 h of peritoneal instillation of 500 mg of cefotaximine were 5.0 ± 1.6 μg ml^-1. The average plasma concentration over 24 h was 6.9 ± 0.4 μg ml^-1 and was no different from that found following a further 9-11 days of successful treatment of the peritonitis. However, the mean dialysate effluent concentration of cefotaxime was increased following the resolution of the peritonitis, 165 ± 22.7 mg per cycle on day 10 or 12 compared with 50.4 ± 7.3 mg per cycle on day 1, suggesting enhanced peritoneal cefotaxime absorption during acute peritonitis. Nevertheless, during both periods, adequate concentrations of cefotaxime were achieved in dialysate to treat local complications, but plasma levels may be inadequate to treat systemic complications due to Staphylococcus albus.

show abstract

“…Similar results have been found with amoxycillin administered to pa tients with peritonitis undergoing intermittent peritoneal dialysis [Jones et al, 1979].…”

Section: Discussionsupporting

confidence: 82%

Pharmacokinetics of Intraperitoneal Cefotaxime Treatment of Peritonitis in Patients on Continous Ambulatory Peritoneal Dialysis

Petersen¹,

Stewart

Catto

et al. 1985

Nephron

View full text Add to dashboard Cite

show abstract

“…Ozgur O (1997) [22] Turkey 100 64 47 60 UBT, histology Munoz de Bustillo E (1998) [23] Spain No description No description 52 63.5 UBT Yildiz A (1999) [24] Turkey 55 72.5 47 65.9 Serology Huang JJ (2000) [25] [33] However, because amoxicillin (AMOX) is mainly excreted from the kidney, especially high plasma concentrations of AMOX in patients on hemodialysis can be harmful, [34,35] and it is necessary to adjust AMOX dosage for hemodialysis patients. In contrast, clarithromycin (CAM), which is primarily metabolized in the liver, is frequently used in eradication regimens because of its high toxicity to H. pylori.…”

Section: Discussionmentioning

confidence: 99%

Eradication ofHelicobacter pyloriin Hemodialysis Patients

et al. 2007

View full text Add to dashboard Cite

Background. Helicobacter pylori (H. pylori) are a causative agent of digestive disease. Although a proton pump inhibitor combined with amoxicillin-clarithromycin is the accepted drug treatment for H. pylori eradication in Japan, there is no consensus treatment for hemodialysis patients. Study. Seventy-seven hemodialysis patients underwent upper digestive tract endoscopy. Biopsy specimens were taken, and histological findings, culture, and rapid urease tests were performed to confirm the presence of H. pylori. H. pylori-positive patients were then administered at random either a seven-day lansoprazole (60 mg a day)-amoxicillin (750 mg a day)-clarithromycin (400 mg a day) (LAC) regimen or a seven-day lansoprazole (60 mg a day)-clarithromycin (400 mg a day) (LC) regimen. The success of H. pylori eradication was determined from histological findings, culture, and rapid urease tests. Results. In 13 of 77 patients (13.6%), ulcers and/or ulcer scars were seen by endoscopy. Thirty-one patients (40.3%) were positive for H. pylori, and 20 patients among them were randomized to one of two regimens: one is seven-day LAC regimen (eleven patients) and the other is seven-day LC regimen (nine patients). Eradication was successful in nine of the eleven patients (72.7%) receiving the LAC regimen, but in only three of the nine patients (33.3%) who underwent the LC regimen. No serious adverse effects were observed with either regimen, and 95% of the patients reported complete compliance. Conclusion. A seven-day low dose LAC regimen is safe and effective and recommended for treatment of H. pylori infection in hemodialysis patients.

show abstract

Comments on Dialysis Solution, Antibiotic Transport, Poisonings, and Novel Uses of Peritoneal Dialysis

Rubin¹

1989

Peritoneal Dialysis

View full text Add to dashboard Cite

Concentrations of amoxycillin in serum and dialysate of uraemic patients undergoing peritoneal dialysis

Cited by 6 publications

References 11 publications

Pharmacokinetics of Intraperitoneal Cefotaxime Treatment of Peritonitis in Patients on Continous Ambulatory Peritoneal Dialysis

Pharmacokinetics of Intraperitoneal Cefotaxime Treatment of Peritonitis in Patients on Continous Ambulatory Peritoneal Dialysis

Eradication ofHelicobacter pyloriin Hemodialysis Patients

Comments on Dialysis Solution, Antibiotic Transport, Poisonings, and Novel Uses of Peritoneal Dialysis

Contact Info

Product

Resources

About